CD38 and acute lymphoblastic leukemia: Another CD38 mAb, isatuximab, is also being tested in phase I/II clinical trials combined with chemotherapy for refractory relapsed AML and ALL in children (ClinicalTrials.gov identifier: NCT03860844).